Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo

Heart and Vessels

Volumn 31, Issue 5, 2016, Pages 783-794

  Heim, Christian ^a   Gebhardt, Julia ^a   Ramsperger Gleixner, Martina ^a   Jacobi, Johannes ^a   Weyand, Michael ^a   Ensminger, Stephan M ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Atherosclerosis; Clopidogrel; Platelets

Indexed keywords

CLOPIDOGREL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CCL2 PROTEIN, MOUSE; LIPID; LYMPHOKINE; MESSENGER RNA; PDGFD PROTEIN, MOUSE; PLATELET DERIVED GROWTH FACTOR; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; BRACHIOCEPHALIC TRUNK; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLUORESCENCE MICROSCOPY; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IN VIVO STUDY; LIPID ANALYSIS; MACROPHAGE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THORACIC AORTA; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; ANIMAL; AORTIC DISEASES; ATHEROSCLEROTIC PLAQUE; BLOOD; C57BL MOUSE; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; TIME FACTOR; VASCULAR REMODELING;

ANIMALS; AORTA, THORACIC; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOMARKERS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; E-SELECTIN; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; LIPIDS; LYMPHOKINES; MICE, INBRED C57BL; MICE, KNOCKOUT; P-SELECTIN; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET-DERIVED GROWTH FACTOR; RNA, MESSENGER; TICLOPIDINE; TIME FACTORS; VASCULAR REMODELING;

EID: 84930789235     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-015-0696-7     Document Type: Article

References (36)

1. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038):1329–1339
2. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179–1189
3. Ohkubo K, Fujimoto Y, Iwata Y, Kitahara H, Kadohira T, Sugimoto K, Morino T, Kobayashi Y (2014) Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. Heart Vessels 29(1):1–6
4. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M (2002) A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196(7):887–896
5. Massberg S, Schurzinger K, Lorenz M, Konrad I, Schulz C, Plesnila N, Kennerknecht E, Rudelius M, Sauer S, Braun S, Kremmer E, Emambokus NR, Frampton J, Gawaz M (2005) Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 112(8):1180–1188
6. Herbert JM (2004) Effects of ADP-receptor antagonism beyond traditional inhibition of platelet aggregation. Expert Opin Investig Drugs 13(5):457–460
7. Solheim S, Pettersen AA, Arnesen H, Seljeflot I (2006) No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 96(5):660–664
8. Azar RR, Kassab R, Zoghbi A, Aboujaoude S, El-Osta H, Ghorra P, Germanos M, Salame E (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151(2):521 e521–521 e524
9. Abele S, Spriewald BM, Ramsperger-Gleixner M, Wollin M, Hiemann NE, Nieswandt B, Weyand M, Ensminger SM (2009) -A35 Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts. Transplantation 87(2):207–216
10. Eckl S, Heim C, Abele-Ohl S, Hoffmann J, Ramsperger-Gleixner M, Weyand M, Ensminger SM (2010) Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts. Transpl Int 23(9):959–966
11. Heim C, Eckl S, Gebhardt J, Weyand M, Ensminger SM (2010) Die unterschätzte Rolle von Thrombozyten bei der Herztransplantation. Zeitschrift für Herz-, Thorax- und Gefäßchirurgie 24(4):241–250
12. Rathouska J, Nemeckova I, Zemankova L, Strasky Z, Jezkova K, Varejckova M, Nachtigal P (2015) Cell adhesion molecules and eNOS expression in aorta of normocholesterolemic mice with different predispositions to atherosclerosis. Heart Vessels 30(2):241–248
13. Afek A, Kogan E, Maysel-Auslender S, Mor A, Regev E, Rubinstein A, Keren G, George J (2009) Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc Res 77(3):364–369
14. Schulz C, Konrad I, Sauer S, Orschiedt L, Koellnberger M, Lorenz R, Walter U, Massberg S (2008) Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. Thromb Haemost 99(1):190–195
15. Abele S, Weyand M, Wollin M, Hiemann NE, Harig F, Fischlein T, Ensminger SM (2006) Clopidogrel reduces the development of transplant arteriosclerosis. J Thorac Cardiovasc Surg 131(5):1161–1166
16. Jacobi J, Maas R, Cardounel AJ, Arend M, Pope AJ, Cordasic N, Heusinger-Ribeiro J, Atzler D, Strobel J, Schwedhelm E, Boger RH, Hilgers KF (2010) Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol 176(5):2559–2570
17. Ensminger SM, Billing JS, Morris PJ, Wood KJ (2000) -E1 Development of a combined cardiac and aortic transplant model to investigate the development of transplant arteriosclerosis in the mouse. J Heart Lung Transplant 19(11):1039–1046
18. Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, Mathieu C (2003) The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 14(1):33–43
19. Nishiyama T, Mishima K, Obara K, Inoue H, Doi T, Kondo S, Saka M, Tabunoki Y, Hattori Y, Kodama T, Tsubota K, Saito I (2007) Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sjogren’s syndrome model mice. Clin Exp Immunol 149(3):586–595
20. Yamamoto T, Nakahata Y, Tanaka M, Yoshida M, Soma H, Shinohara K, Yasuda A, Mamine T, Takumi T (2005) Acute physical stress elevates mouse period1 mRNA expression in mouse peripheral tissues via a glucocorticoid-responsive element. J Biol Chem 280(51):42036–42043
21. Lusis AJ (2000) Atherosclerosis. Nature 407(6801):233–241
22. Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340(2):115–126
23. Kher N, Marsh JD (2004) Pathobiology of atherosclerosis–a brief review. Semin Thromb Hemost 30(6):665–672
24. Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115(12):3378–3384
25. −/− mice. Circ Res 103(10):1181–1189
26. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12(2):178–180
27. Mor A, Planer D, Luboshits G, Afek A, Metzger S, Chajek-Shaul T, Keren G, George J (2007) Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 27(4):893–900
28. Heim C, Eckl S, Preidl R, Ramsperger-Gleixner M, Koch N, Goldmann K, Spriewald BM, Weyand M, Ensminger SM (2015) Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. Eur J Cardiothorac Surg 47(1):180–187
29. Burger PC, Wagner DD (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101(7):2661–2666
30. Li G, Sanders JM, Bevard MH, Sun Z, Chumley JW, Galkina EV, Ley K, Sarembock IJ (2008) CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 172(4):1141–1152
31. Lindemann S, Kramer B, Seizer P, Gawaz M (2007) Platelets, inflammation and atherosclerosis. J Thromb Haemost 5(Suppl 1):203–211
32. Gawaz M, Neumann FJ, Dickfeld T, Koch W, Laugwitz KL, Adelsberger H, Langenbrink K, Page S, Neumeier D, Schomig A, Brand K (1998) Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 98(12):1164–1171
33. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS (2001) A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107(10):1255–1262
34. −/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394(6696):894–897
35. Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868–874
36. Wood KJ, Goto R (2012) Mechanisms of rejection: current perspectives. Transplantation 93(1):1–10